Abstract
Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular, endocrinological and psychogenic components described. However, about 50-85% of ED population report the presence of one or more comorbidities i.e. hypertension, diabetes, cardiovascular disease, dyslipidemia which all impair endothelial function and, erection is a basically vascular event that necessitates an intact endothelium to occur. Hence, ED may be mostly considered as the clinical manifestation of a disease affecting penile circulation as a part of a generalized vascular disorder due to atherosclerosis. Orally active drugs, i.e. phosphodiesterase type-5 inhibitors (PDE5-i), are a group of on-demand drugs licensed for ED treatment and appear to offer advantages over past therapies in terms of ease of administration and cost, and they are now widely advocated as first-line therapy. The recent discovery that chronic not on-demand administration of these drugs may improve erectile and endothelial response in men previously unresponding to on-demand regimes, opens a new scenario in the treatment of men with ED and comorbidities. Finally, the recent approval of PDE5-i sildenafil for the treatment of pulmonary arterial hypertension represents the new challenge for these class of drugs. Aim of this article will be to provide an update on the pathophysiology of ED and how to use of different available PDE5-i in approaching sexual dysfunctional men, pointing out on their characteristic of efficacy and safety and different indications in special subpopulations.
Keywords: Phosphodiesterase 5 inhibitors, Erection, Cardiovascular disease, Endothelium, Efficacy, Safety
Current Pharmaceutical Design
Title: Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Volume: 12 Issue: 27
Author(s): Antonio Aversa, Roberto Bruzziches, Marcello Pili and Giovanni Spera
Affiliation:
Keywords: Phosphodiesterase 5 inhibitors, Erection, Cardiovascular disease, Endothelium, Efficacy, Safety
Abstract: Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular, endocrinological and psychogenic components described. However, about 50-85% of ED population report the presence of one or more comorbidities i.e. hypertension, diabetes, cardiovascular disease, dyslipidemia which all impair endothelial function and, erection is a basically vascular event that necessitates an intact endothelium to occur. Hence, ED may be mostly considered as the clinical manifestation of a disease affecting penile circulation as a part of a generalized vascular disorder due to atherosclerosis. Orally active drugs, i.e. phosphodiesterase type-5 inhibitors (PDE5-i), are a group of on-demand drugs licensed for ED treatment and appear to offer advantages over past therapies in terms of ease of administration and cost, and they are now widely advocated as first-line therapy. The recent discovery that chronic not on-demand administration of these drugs may improve erectile and endothelial response in men previously unresponding to on-demand regimes, opens a new scenario in the treatment of men with ED and comorbidities. Finally, the recent approval of PDE5-i sildenafil for the treatment of pulmonary arterial hypertension represents the new challenge for these class of drugs. Aim of this article will be to provide an update on the pathophysiology of ED and how to use of different available PDE5-i in approaching sexual dysfunctional men, pointing out on their characteristic of efficacy and safety and different indications in special subpopulations.
Export Options
About this article
Cite this article as:
Aversa Antonio, Bruzziches Roberto, Pili Marcello and Spera Giovanni, Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction, Current Pharmaceutical Design 2006; 12 (27) . https://dx.doi.org/10.2174/138161206778343046
DOI https://dx.doi.org/10.2174/138161206778343046 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms
Current Cardiology Reviews Addiction Liability of Pharmacotherapeutic Interventions in Obesity
Current Pharmaceutical Design Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Cerebral Hypoperfusion in Hereditary Coproporphyria (HCP): A Single Photon Emission Computed Tomography (SPECT) Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Antioxidant Activity, α-glucosidase Inhibitory Activity and Chemoprotective Properties of Rhododendron brachycarpum Leaves Extracts
Current Pharmaceutical Biotechnology Episcleritis and Scleritis in Rheumatic Disease
Current Rheumatology Reviews Editorial [Hot Topic: Drugs Targeting Atherosclerosis: Current and Emerging Approaches (Executive Editors: Vangelis G. Manolopoulos and Anna Tavridou)]
Current Pharmaceutical Design Editorial: [Hot Topic: Nanotechnology and Patents in Agriculture, Food Technology, Nutrition and Medicine - Advantages and Risks]
Recent Patents on Food, Nutrition & Agriculture The Current Role of Statin Therapy in the Treatment of Atrial Fibrillation
Cardiovascular & Hematological Agents in Medicinal Chemistry Gender-Specific Relationship Between Uric Acid Levels and Prognosis After Cerebral Venous Thrombosis
Current Neurovascular Research Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease
Current Drug Metabolism Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Current Medicinal Chemistry The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets Podocyte Mitosis – A Catastrophe
Current Molecular Medicine High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects
Current Pharmaceutical Design Non-ACE Pathway-induced Angiotensin II Production
Current Pharmaceutical Design Steroids and the Immune Response in Graves Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Hormones and the Autonomic Nervous System are Involved in Suprachiasmatic Nucleus Modulation of Glucose Homeostasis
Current Diabetes Reviews Pharmacological Agents in the Treatment of Venous Disease: An Update of the Available Evidence
Current Vascular Pharmacology